WASHINGTON — In a new approach to HIV prevention, women modestly reduced their risk of infection by inserting a vaginal ring coated with an anti-AIDS drug once a month, according to two long-awaited studies from Africa.
The ring proved safe although it cut HIV infections by less than a third overall, researchers reported Monday. But surprisingly, it worked far better in women 25 and older, leaving researchers wondering if the youngest women, who got little to no benefit, simply didn't use the device properly.
"For a woman to have a prevention tool that she can control is an incredibly important goal," said Dr. Jared Baeten of the University of Washington, who led a National Institutes of Health-funded study of the ring. "I want rings, pills and other strategies to be on the shelf for women so they can make choices for what's going to work for them."
Despite the questions the studies raise, the non-profit International Partnership for Microbicides said it considered the results promising enough to seek appropriate regulatory approval for wider use in parts of Africa.
"You can't just say, 'Until something is perfect, we're going to wait,' " said Dr. Zeda Rosenberg, founding chief executive officer of IPM. "We have to give women options."
Women make up more than half of the nearly 37 million people worldwide living with HIV, most of them in hard-hit Africa, and scientists have long sought tools to help them protect themselves when their partners won't use a condom.
Aside from condoms, healthy people also can take a daily anti-AIDS pill to lower their risk from an infected partner. That so-called "pre-exposure prophylaxis" isn't widely available in poor countries, and other attempts at HIV-blocking vaginal gels haven't yet panned out.
But the age disparity found in the vaginal ring studies is so puzzling that the NIH plans to consult with outside experts on next research steps.
While women need a discreet form of HIV prevention, "it's going to be absolutely critical" to determine if the younger women really didn't follow instructions, or if there was some biological difference, cautioned Dr. Anthony Fauci, director of NIH's National Institute for Allergy and Infectious Diseases.
Vaginal rings are sold in the U.S. for birth control, but the anti-AIDS version tested in Africa contained no contraception. Instead, it slowly oozes an experimental virus-blocking drug named dapivirine into the surrounding vaginal tissue. Women would replace the ring once a month, when it was time for another dose.
Two studies involving more than 4,500 women in Africa are being presented at the Retrovirus Conference in Boston, comparing women who used the dapivirine ring with those given an identical-looking but drug-free version. It offered modest protection, reducing by 27 per cent to 31 per cent the participants' overall risk of HIV.
But closer inspection of the large NIH-funded ASPIRE study in Malawi, South Africa, Uganda and Zimbabwe turned up something odd. Ring users who were 25 and older were 61 per cent less likely to be infected while those ages 18 to 21 essentially got no benefit, Baeten said.
While the ring is designed to stay in place for an entire month before being replaced, there are signs the younger women didn't use it as regularly, said Baeten, whose results also were published online Monday in the New England Journal of Medicine. He said women had to get comfortable with the how to use a device they'd never seen before, but those who used the ring continuously saw protection that continued throughout the 2 1/2-year study.
"The ring must be used consistently to achieve protection," the IPM's Annalene Nel told reporters Monday as she discussed the second study, called the Ring Study. Conducted in South Africa and Uganda, that study likewise showed a trend toward greater protection for women over 21, she said.
While that study isn't completed yet, the IPM said South African regulators asked researchers to switch all the remaining study participants to the dapivirine-coated ring rather than the placebo version.
Early studies of those daily anti-AIDS pills also found less protection in younger people, who did better at sticking with the tablets only after their effectiveness was proven, said Mitchell Warren, executive director of AVAC, which advocates for a range of HIV prevention tools. He said there is "a global imperative" to answer remaining questions about the ring.
Lauran Neergaard, The Associated Press